Moderna Refocuses On Rare Disease Pipeline As Leadership Evolves

Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic ...
Medical Xpress

Research reveals new treatment strategy for propionic acidemia

Propionic acidemia is caused by mutations in an enzyme called propionyl-CoA carboxylase. CoA is a helper molecule essential for energy metabolism. Propionic acidemia is typically managed by diet. The ...

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolioCollaboration combines Moderna’s expertise in mRNA technology for ...

Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...
Fierce Biotech

Moderna offloads late-stage rare disease drug to Recordati for $50M upfront

Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...
Monthly Prescribing Reference

Investigational mRNA Therapeutic Fast-Tracked for Propionic Acidemia

Cholesterol bloodstream The FDA has granted Fast Track designation to mRNA-3927 (Moderna), an investigational mRNA therapeutic for propionic acidemia. The Food and Drug Administration (FDA) has ...
Monthly Prescribing Reference

Carbaglu Approved for Hyperammonemia in Propionic Acidemia, Methylmalonic Acidemia

The Food and Drug Administration (FDA) has approved a new indication for Carbaglu ® (carglumic acid; Recordati Rare Diseases) for use as adjunctive therapy in the treatment of acute hyperammonemia due ...
Nasdaq

Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)

mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944 (antibody against Chikungunya virus) and mRNA-3704 (methylmalonic acidemia) “Fast Track designation underscores the urgent need for a ...
ksn.com

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, ...
Nasdaq

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting

CAMBRIDGE, MA / ACCESSWIRE / May 19, 2023 / Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 ...
Chicago Tribune

Deerfield H.S. School Chest drive raises funds, awareness for local cause

Creating awareness for a little known disease — propionic acidemia — was important to students who raised money during the annual Deerfield High School School Chest drive this year because the cause ...